Cargando…
Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy
The appearance of chemoresistance in cancer is a major issue. The main barriers to conventional tumor chemotherapy are undesirable toxic effects and multidrug resistance. Cancer nanotherapeutics were developed to get around the drawbacks of conventional chemotherapy. Through clinical evaluation of t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634039/ https://www.ncbi.nlm.nih.gov/pubmed/36338748 http://dx.doi.org/10.3389/fonc.2022.1042125 |
_version_ | 1784824378857357312 |
---|---|
author | Katopodi, Theodora Petanidis, Savvas Tsavlis, Drosos Anestakis, Doxakis Charalampidis, Charalampos Chatziprodromidou, Ioanna Eskitzis, Panagiotis Zarogoulidis, Paul Kosmidis, Christoforos Matthaios, Dimitris Porpodis, Konstantinos |
author_facet | Katopodi, Theodora Petanidis, Savvas Tsavlis, Drosos Anestakis, Doxakis Charalampidis, Charalampos Chatziprodromidou, Ioanna Eskitzis, Panagiotis Zarogoulidis, Paul Kosmidis, Christoforos Matthaios, Dimitris Porpodis, Konstantinos |
author_sort | Katopodi, Theodora |
collection | PubMed |
description | The appearance of chemoresistance in cancer is a major issue. The main barriers to conventional tumor chemotherapy are undesirable toxic effects and multidrug resistance. Cancer nanotherapeutics were developed to get around the drawbacks of conventional chemotherapy. Through clinical evaluation of thoughtfully developed nano delivery systems, cancer nanotherapeutics have recently offered unmatched potential to comprehend and combat drug resistance and toxicity. In different design approaches, including passive targeting, active targeting, nanomedicine, and multimodal nanomedicine combination therapy, were successful in treating cancer in this situation. Even though cancer nanotherapy has achieved considerable technological development, tumor biology complexity and heterogeneity and a lack of full knowledge of nano-bio interactions remain important hurdles to future clinical translation and commercialization. The recent developments and advancements in cancer nanotherapeutics utilizing a wide variety of nanomaterial-based platforms to overcome cancer treatment resistance are covered in this article. Additionally, an evaluation of different nanotherapeutics-based approaches to cancer treatment, such as tumor microenvironment targeted techniques, sophisticated delivery methods for the precise targeting of cancer stem cells, as well as an update on clinical studies are discussed. Lastly, the potential for cancer nanotherapeutics to overcome tumor relapse and the therapeutic effects and targeted efficacies of modern nanosystems are analyzed. |
format | Online Article Text |
id | pubmed-9634039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96340392022-11-05 Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy Katopodi, Theodora Petanidis, Savvas Tsavlis, Drosos Anestakis, Doxakis Charalampidis, Charalampos Chatziprodromidou, Ioanna Eskitzis, Panagiotis Zarogoulidis, Paul Kosmidis, Christoforos Matthaios, Dimitris Porpodis, Konstantinos Front Oncol Oncology The appearance of chemoresistance in cancer is a major issue. The main barriers to conventional tumor chemotherapy are undesirable toxic effects and multidrug resistance. Cancer nanotherapeutics were developed to get around the drawbacks of conventional chemotherapy. Through clinical evaluation of thoughtfully developed nano delivery systems, cancer nanotherapeutics have recently offered unmatched potential to comprehend and combat drug resistance and toxicity. In different design approaches, including passive targeting, active targeting, nanomedicine, and multimodal nanomedicine combination therapy, were successful in treating cancer in this situation. Even though cancer nanotherapy has achieved considerable technological development, tumor biology complexity and heterogeneity and a lack of full knowledge of nano-bio interactions remain important hurdles to future clinical translation and commercialization. The recent developments and advancements in cancer nanotherapeutics utilizing a wide variety of nanomaterial-based platforms to overcome cancer treatment resistance are covered in this article. Additionally, an evaluation of different nanotherapeutics-based approaches to cancer treatment, such as tumor microenvironment targeted techniques, sophisticated delivery methods for the precise targeting of cancer stem cells, as well as an update on clinical studies are discussed. Lastly, the potential for cancer nanotherapeutics to overcome tumor relapse and the therapeutic effects and targeted efficacies of modern nanosystems are analyzed. Frontiers Media S.A. 2022-10-21 /pmc/articles/PMC9634039/ /pubmed/36338748 http://dx.doi.org/10.3389/fonc.2022.1042125 Text en Copyright © 2022 Katopodi, Petanidis, Tsavlis, Anestakis, Charalampidis, Chatziprodromidou, Eskitzis, Zarogoulidis, Kosmidis, Matthaios and Porpodis https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Katopodi, Theodora Petanidis, Savvas Tsavlis, Drosos Anestakis, Doxakis Charalampidis, Charalampos Chatziprodromidou, Ioanna Eskitzis, Panagiotis Zarogoulidis, Paul Kosmidis, Christoforos Matthaios, Dimitris Porpodis, Konstantinos Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy |
title | Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy |
title_full | Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy |
title_fullStr | Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy |
title_full_unstemmed | Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy |
title_short | Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy |
title_sort | engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634039/ https://www.ncbi.nlm.nih.gov/pubmed/36338748 http://dx.doi.org/10.3389/fonc.2022.1042125 |
work_keys_str_mv | AT katopoditheodora engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy AT petanidissavvas engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy AT tsavlisdrosos engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy AT anestakisdoxakis engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy AT charalampidischaralampos engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy AT chatziprodromidouioanna engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy AT eskitzispanagiotis engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy AT zarogoulidispaul engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy AT kosmidischristoforos engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy AT matthaiosdimitris engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy AT porpodiskonstantinos engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy |